<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2298">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131243</url>
  </required_header>
  <id_info>
    <org_study_id>FZ-CON-001</org_study_id>
    <nct_id>NCT05131243</nct_id>
  </id_info>
  <brief_title>the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer</brief_title>
  <official_title>the Role of ctDNA in Predicting the Recurrence Risk of Stage Ⅱ and Ⅲ Colorectal Cancer and the Dynamic Changes in ctDNA of Patients With Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to observe the relationship between ctDNA as a molecular marker&#xD;
      of colorectal cancer and the risk of postoperative recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical study, ctDNA will be detected in postoperative patients with stage Ⅱ and Ⅲ&#xD;
      colorectal cancer to evaluate the correlation between ctDNA and the risk of postoperative&#xD;
      recurrence. According to the dynamic changes of ctDNA after adjuvant chemotherapy, the&#xD;
      correlation between ctDNA and postoperative DFS will be compared, and the feasibility of&#xD;
      ctDNA as a molecular marker to evaluate the risk of postoperative recurrence of colorectal&#xD;
      cancer will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ctDNA status</measure>
    <time_frame>Two weeks</time_frame>
    <description>Detect postoperative tissue ctDNA status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ctDNA dynamic detection</measure>
    <time_frame>6 months</time_frame>
    <description>ctDNA dynamic monitoring during postoperative adjuvant chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imaging examination</measure>
    <time_frame>6 months</time_frame>
    <description>Imaging examination during postoperative adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Marker examination</measure>
    <time_frame>6 months</time_frame>
    <description>Tumor marker examination during postoperative adjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer Stage II</condition>
  <condition>Colorectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>ctDNA positive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative ctDNA-positive patients will receive chemotherapy for 6 months.The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ctDNA negative patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperative ctDNA-negative patients will receive chemotherapy for 3 months. The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemotherapy time</intervention_name>
    <description>6 months of chemotherapy</description>
    <arm_group_label>ctDNA positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemotherapy time</intervention_name>
    <description>3 months of chemotherapy</description>
    <arm_group_label>ctDNA negative patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients with colorectal cancer diagnosed pathologically as stage Ⅱ and stage Ⅲ.&#xD;
&#xD;
          -  2. The patient underwent radical surgical treatment.&#xD;
&#xD;
          -  3. The patient has the results of genetic genetic testing for gastrointestinal tumors,&#xD;
             including the genetic mutation status of MMR genes and related genes (MLH1, MSH2,&#xD;
             MSH6, PMS2, MLH3, EPCAM).&#xD;
&#xD;
          -  4. The patient understands and is willing to sign a written informed consent document.&#xD;
&#xD;
          -  5. During the treatment process, the patient can cooperate to provide samples of each&#xD;
             node.&#xD;
&#xD;
          -  6. The patient can provide corresponding clinical materials, including but not limited&#xD;
             to case diagnosis, imaging evaluation, and serum protein marker test results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. The patient cannot provide a complete and qualified specimen.&#xD;
&#xD;
          -  2. The patient has other primary malignant tumors or serious medical illnesses.&#xD;
&#xD;
          -  3. The patient cannot cooperate with the follow-up.&#xD;
&#xD;
          -  4. Conditions that other researchers deemed inappropriate for continuing to&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaojie Wang</last_name>
    <phone>13509399900</phone>
    <email>634793899@qq.com</email>
  </overall_contact>
  <reference>
    <citation>Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci. 2015 Jun 19;16(6):14122-42. doi: 10.3390/ijms160614122. Review.</citation>
    <PMID>26101870</PMID>
  </reference>
  <reference>
    <citation>Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep;14(9):985-90. doi: 10.1038/nm.1789. Epub 2007 Jul 31.</citation>
    <PMID>18670422</PMID>
  </reference>
  <reference>
    <citation>Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.</citation>
    <PMID>23484797</PMID>
  </reference>
  <reference>
    <citation>Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.</citation>
    <PMID>26311728</PMID>
  </reference>
  <reference>
    <citation>Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219.</citation>
    <PMID>27384348</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ctDNA</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

